Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm
Acta Haematologica · 04.06.2026 · 1-9
DOI: 10.1159/000552815 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 04.06.2026. Verfasst von Alexander Ambinder und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Johns Hopkins Hospital, Baltimore, Maryland, USA, aambind1@jhmi.edu. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Tagraxofusp, a first-in-class CD123-targeted therapy, is the only approved treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Shared care models enable coordination and care delivery between specialized cancer treatment centers and local institutions, allowing eligible patients to receive tagraxofusp. Summary: This review provides guidance on best practices for effective shared care implementation for tagraxofusp in patients with BPDCN, including appropriate patient selection, adequate local institutional readiness, proactive collaboration and communication between institutions, integrated comanagement between institutions, and requisite staff, patient, and caregiver education. Key Messages: Shared care is particularly suitable for tagraxofusp treatment, as adverse events can be grade 3 or greater, but typically only occur in cycle 1, if they are to occur at all. Based on clinical experience, this article discusses the application of a shared care model for tagraxofusp treatment in BPDCN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Johns Hopkins Hospital, Baltimore, Maryland, USA, aambind1@jhmi.edu.
- Duke University School of Medicine, Durham, North Carolina, USA.
- Baylor Scott and White Health, Dallas, Texas, USA.
- Huntsman Cancer Institute, Salt Lake City, Utah, USA.
- Hackensack University Medical Center, Hackensack, New Jersey, USA.
- Menarini Group, New York, New York, USA.
Zitieren
APA
Ambinder, A., LeBlanc, T. W., Levy, M. Y., Patel, A. B., McCloskey, J., Duffield, E., Katsetos, J., & Mannis, G. (2026). Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm. Acta Haematologica, 1-9. https://doi.org/10.1159/000552815
Vancouver
Ambinder A, LeBlanc TW, Levy MY, Patel AB, McCloskey J, Duffield E, et al. Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm. Acta Haematologica. 2026:1-9. doi:10.1159/000552815
BibTeX
@article{Ambinder2026,
author = {Ambinder, Alexander and LeBlanc, Thomas W and Levy, M Yair and Patel, Ami B and McCloskey, James and Duffield, Erin and Katsetos, John and Mannis, Gabriel},
title = {Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm},
journal = {Acta Haematologica},
year = {2026},
pages = {1--9},
doi = {10.1159/000552815}
}
EUVIMED